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Hypertriglyceridemia is a Major Factor Associated With 
Elevated Levels of Small Dense LDL Cholesterol in 
Patients With Metabolic Syndrome
Yonggeun Cho, M.D.1,4,*, Sang-Guk Lee, M.D.2,*, Sun Ha Jee, Ph.D.3, and Jeong-Ho Kim, M.D.2
Departments of Microbiology and Immunology1, Laboratory Medicine2; Epidemiology and Health Promotion3, Graduate School of Public Health; and Brain 
Korea 21 PLUS Project for Medical Science4, Yonsei University College of Medicine, Seoul, Korea
Background: We aimed to determine the major contributing component of metabolic syn-
drome (MetS) that results in an elevated small dense LDL cholesterol (sdLDL-C) concen-
tration and sdLDL-C/LDL-C ratio. 
Methods: Four hundred and forty-seven subjects (225 men; 222 women) with MetS were 
randomly selected from the Korean Metabolic Syndrome Research Initiatives-Seoul cohort 
study. Age- and sex-matched healthy controls (181 men; 179 women) were also randomly 
selected from the same cohort. 
Results: A comparison of the median values of the sdLDL-C concentration between sub-
groups, divided according to whether subjects met or did not meet the criteria for each 
MetS component in patients with MetS, revealed a significant difference in the sdLDL-C 
concentration only between subgroups divided according to whether subjects met or did 
not meet the triglyceride (TG) criteria (P <0.05 for each gender). The TG level showed a 
good correlation with sdLDL-C concentration (correlation coefficients [r]=0.543 for men; 
0.653 for women) and the sdLDL-C/LDL-C ratio (r=0.789 for men; 0.745 for women). Mul-
tiple linear regression analyses conducted for the MetS group concordantly identified TG 
as one of the most significant contributors to sdLDL-C concentration (β=0.1747±0.0105, 
P <0.0001) and the sdLDL-C/LDL-C ratio (β=6.9518±0.3011, P <0.0001).
Conclusions: Among five MetS components, only the abnormal TG level was a differenti-
ating factor for sdLDL-C concentration and sdLDL-C/LDL-C ratio. These results were re-
producible in both genders, with or without MetS. 
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INTRODUCTION
Elevated LDL cholesterol (LDL-C) is a major cause of cardiovas-
cular disease (CVD), and clinical trials have conclusively shown 
that LDL-C-lowering therapy reduces the risk of developing CVD 
[1, 2]. For these reasons, the United States National Institutes 
of Health National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP) III continues to identify elevated LDL-C 
as the primary target of cholesterol-lowering therapy [3]. How-
ever, measuring LDL-C concentration alone was insufficient to 
identify all individuals with incident CVD since a substantial pro-
portion of these events occur in patients with a normal LDL-C 
concentration [4]. This has led to a search for other factors that 
may be implicated in the pathogenesis of atherosclerosis and 
CVD.
 Metabolic syndrome (MetS), a constellation of CVD risk fac-
tors relating to the concentration of certain lipids other than LDL-
C (hypertriglyceridemia, low HDL cholesterol [HDL-C], and insu-
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lin resistance) and non-lipid factors (hypertension and abdomi-
nal obesity), has been proposed as a criterion that would be help-
ful in identifying those patients who are at high risk of CVD re-
gardless of LDL-C level [5]. The ATP III report has identified MetS 
as a secondary target of therapy in the management of CVD, in 
addition to LDL-C-lowering therapy [3, 6].
 Small dense LDL (sdLDL), which is not a MetS criterion, is a 
distinct LDL subclass primarily identified through size separation 
using gradient gel electrophoresis [7]. sdLDL has gained atten-
tion because of its pathogenicity and correlation with metabolic 
disease. It has been shown to have a higher degree of penetra-
tion of the arterial wall, a lower binding affinity for LDL receptors, 
a prolonged plasma half-life, and a lower resistance to oxidative 
stress relative to large buoyant LDL [8, 9]. Clinical studies have 
consistently demonstrated that the accumulation of sdLDL par-
ticles in the plasma is associated with an increased risk of CVD 
[10]. Furthermore, the measurement of sdLDL cholesterol (sdLDL-
C) concentration was useful in the assessment of the presence 
of CVD [11,12] and its severity [13]. In addition, a recent publi-
cation by Arai et al. [14] demonstrated the utility of the sdLDL-C 
concentration as a predictive marker for CVD incidence.
 Patients with MetS may not present with an elevated LDL-C 
concentration. However, a qualitative abnormality in LDL-C, 
such as sdLDL-C, is associated with MetS [15]. Nozue et al. [16] 
reported that the sdLDL-C concentration measured by using the 
heparin–magnesium precipitation method was significantly higher 
in patients with coronary artery disease and MetS than in pati-
ents without MetS. Nakano et al. [17] and Sugino et al. [18] con-
ducted cross-sectional studies using patients with MetS and heal-
thy controls, and observed a higher concentration of sdLDL-C in 
patients with MetS. However, the component of MetS that is most 
closely associated with an elevated sdLDL-C concentration has 
not been identified.
 In this study, we evaluated the association between sdLDL-C 
concentration or sdLDL-C/LDL-C ratio and metabolic parameters 
that included each component of MetS, and attempted to iden-
tify the major component of MetS contributing to an elevated 
sdLDL-C concentration. 
METHODS
1. Study participants
Four hundred and forty-seven subjects (225 men; 222 women) 
with MetS were obtained from the Korean Metabolic Syndrome 
Research Initiatives–Seoul cohort study (2006-2010) [19] by 
using simple random sampling in subgroup with MetS. Age- and 
sex-matched healthy controls (181 men; 179 women) without 
MetS were also randomly selected from healthy subgroup of the 
same cohort. All subjects completed the lifestyle questionnaire 
and anthropometric survey, and serum samples for biochemical 
tests were collected in accordance with the protocols outlined 
by the Institutional Review Board of Severance Hospital, Yonsei 
University, Seoul, Korea. Serum samples were stored frozen be-
low -80°C until further analyses. 
2. Diagnosis of MetS and definition of healthy status
MetS was diagnosed according to the NCEP ATP III definition of 
MetS, with the exception of two components, i.e., fasting glu-
cose (fasting blood glucose >5.6 mmol/L) and waist circumfer-
ence (waist circumference [WC]; >90 cm for mem; >85 cm 
for women), which had been modified for the Asian population 
[20]. Healthy population was defined as individuals without re-
nal disease, hepatic disease, infectious diseases, or malignancy, 
as well as, history of familial lipid disorders or dyslipidemia-re-
lated diseases. 
3. Biochemical tests
Frozen serum samples of the study participants were thawed 
and used for biochemical tests. Serum glucose concentrations 
were measured by using the hexokinase method (Roche Diag-
nostics, Mannheim, Germany) with a Hitachi 7600 clinical chem-
istry analyzer (Hitachi Ltd., Tokyo, Japan). Total cholesterol (TC) 
and triglyceride (TG) concentrations were determined by using 
enzymatic methods (Sekisui, Tokyo, Japan and Roche Diagnos-
tics, respectively), and HDL-C and LDL-C were determined by 
using a direct enzymatic procedure (Sekisui) with a Hitachi 7600 
analyzer. Serum sdLDL-C concentrations were measured by us-
ing a homogeneous enzymatic assay (Denka Seiken, Tokyo, Ja-
pan) with a Hitachi-7600 analyzer. Serum insulin concentration 
was determined by using an automated enzyme chemilumines-
cence immunoassay (DxI; Beckman Coulter, Brea, CA, USA). 
As a surrogate index of insulin resistance, homeostasis model 
assessment of insulin resistance (HOMA-IR) was calculated by 
using the formula of Matthews et al. [21] as follows: fasting plasma 
insulin (mIU/L)×fasting plasma glucose (mmol/L)/22.5.
4. Statistical analyses
Participants’ characteristics were compared according to MetS 
status by using the Mann-Whitney’s U tests for continuous mea-
sures and chi-square tests for categorical measures. The median 
values of sdLDL-C concentration were compared between sub-
groups classified according to whether subjects met or did not 
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meet the criteria for each MetS component. A correlation between 
the sdLDL-C concentration or sdLDL-C/LDL-C ratio and age or an-
other metabolic parameter was examined. The strength of correla-
tion was interpreted according to the size of correlation coefficient 
(r) as strong (0.8≤ |r<1), moderate (0.5≤|r|<0.8), or weak (0.1 
≤|r|<0.5). Multiple linear regression analysis by the “enter” pro-
cedure was performed to identify the independent variables asso-
ciated with plasma sdLDL-C concentration. To perform this analy-
sis, the criteria for MetS (WC, TG, HDL-C, systolic blood pressure, 
diastolic blood pressure [DBP], fasting glucose), age, and LDL-C 
were included in the model. All statistical analyses were conducted 
by using the Analyse-it Me thod Evaluation Edition version 2.22 
software (Analyse-it Software Ltd., Leeds, UK), GraphPad Prism 
version 6.04 (GraphPad Software, La Jolla, CA, USA), or PASW 
Statistics 18.0.0 tool (IBM Corp., Armonk, NY, USA). P values 
<0.05 were considered statistically significant.
RESULTS
1. Characteristics of the study groups
The characteristics of participants grouped by MetS status are 
summarized in Table 1. Subjects with MetS had a significantly 
higher sdLDL-C concentration and sdLDL-C/LDL-C ratio than 
healthy controls, in both men and women (Fig. 1). In addition, 
subjects presenting with MetS had a higher body mass index, 
fasting insulin level, HOMA-IR, and non-HDL-C concentration 
than healthy controls in both genders (Table 1). TC and LDL-C 
concentrations were higher in women with MetS than without 
MetS. Reference intervals for sdLDL-C, determined by using 
non-parametric methods (2.5 and 97.5 percentiles) in healthy 
controls, were 0.30-1.86 mmol/L for men and 0.27-1.61 mmol/
L for women.
 Subjects presenting with MetS included a higher percentage 
Table 1. Baseline characteristics of the study population
Characteristic
Men (n=406) Women (n=401)
Healthy  population MetS P value Healthy population MetS P value
Number 181 225 - 179 222 -
Age (yr) 46 (40-54) 51 (43-57) <0.001 45 (38-53) 56 (50-62) <0.001
BMI (kg/m2) 24.10 (22.38-25.68) 26.56 (25.20-28.15) <0.001 21.91 (20.80-23.79) 25.55 (24.25-27.48) <0.001
WC (cm) 84 (79-88) 92 (90-96) <0.001 73 (69-77) 84 (81-88) <0.001
SBP (mm Hg) 116 (111-122) 128 (119-135) <0.001 109 (104-116) 125 (116-137) <0.001
DBP (mm Hg) 77 (69-81) 88 (82-93) <0.001 70 (65-78) 82 (75-87) <0.001
Fasting glucose (mmol/L) 4.83 (4.55-5.05) 5.61 (5.00-6.49) <0.001 4.66 (4.38-4.88) 5.27 (4.83-6.44) <0.001
Fasting insulin (mIU/L) 4.1 (2.8-5.6) 6.5 (4.8-8.7) <0.001 3.8 (2.5-4.8) 5.3 (3.9-7.1) <0.001
HOMA-IR 0.894 (0.655-1.302) 1.687 (1.184-2.369) <0.001 0.818 (0.524-1.039) 1.302 (0.984-1.888) <0.001
TC (mmol/L) 4.82 (4.33-5.34) 4.95 (4.33-5.59) 0.123 4.74 (4.25-5.46) 5.21 (4.61-5.78) <0.001
TG (mmol/L) 1.42 (1.01-2.02) 2.43 (1.88-3.21) <0.001 0.95 (0.80-1.41) 2.00 (1.73-2.52) <0.001
HDL-C (mmol/L) 1.27 (1.11-1.48) 1.01 (0.93-1.17) <0.001 1.53 (1.32-1.79) 1.17 (1.06-1.35) <0.001
LDL-C (mmol/L) 3.08 (2.69-3.50) 3.08 (2.59-3.52) 0.840 2.93 (2.43-3.55) 3.32 (2.82-3.89) <0.001
Non-HDL-C (mmol/L) 3.52 (2.98-3.96) 3.86 (3.26-4.53) <0.001 3.19 (2.69-3.91) 3.94 (3.39-4.61) <0.001
sdLDL-C (mmol/L) 0.88 (0.62-1.20) 1.16 (0.91-1.60) <0.001 0.64 (0.47-0.89) 1.10 (0.85-1.39) <0.001
sdLDL-C (mmol/L), 2.5-97.5 percentile 0.30-1.86 0.49-2.31 - 0.27-1.61 0.39-2.22 -
sdLDL-C/LDL-C (%) 28.08 (21.74-37.00) 39.29 (32.21-48.50) <0.001 21.37 (18.21-26.06) 33.20 (26.93-40.07) <0.001
LDL-C <2.6 mmol/L 20.40% 24.40% 0.3383* 30.20% 17.10% 0.0020*
LDL-C >4.14 mmol/L 4.40% 11.60% 0.0099* 11.20% 17.60% 0.0723*
sdLDL-C <0.5 mmol/L 13.80% 2.70% <0.0001* 31.80% 6.30% <0.0001*
sdLDL-C >1.0 mmol/L 38.10% 60.90% <0.0001* 15.10% 56.80% <0.0001*
Values are presented as the median (interquartile range), with the exception of the frequency data. 
*The chi-square test was employed to compare frequency data. Other characteristics were analyzed using the Mann-Whitney’s U test.
Abbreviations: MetS, metabolic syndrome; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HOMA-IR, homeostasis model of insulin resistance; TC, total cholesterol; TG, triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; sdLDL-C, small 
dense LDL cholesterol.
Cho Y, et al.
Triglyceride and sdLDL-C in MetS patients
http://dx.doi.org/10.3343/alm.2015.35.6.586 www.annlabmed.org  589
with high LDL-C (>4.14 mmol/L) as defined by the NCEP [3] 
than healthy men and women. However, the percentage with 
optimal LDL-C (<2.6 mmol/L) was lower in individuals with MetS 
than without MetS for women only. The proportion of subjects 
with a sdLDL-C concentration <0.5 mmol/L was significantly 
lower among both men and women with MetS than without MetS 
(Table 1). The proportion with sdLDL-C >1.0 mmol/L was higher 
in individuals with MetS than without MetS.
2.  Differences in sdLDL-C concentration or sdLDL-C/LDL-C 
ratio in relation to the presence or absence of each MetS 
component
Fig. 1 shows that patients with MetS had higher sdLDL-C con-
centrations than healthy controls, in both men and women. When 
the median values of sdLDL-C concentration were compared 
between subgroups, divided according to whether subjects met 
or did not meet the criteria for each MetS component (Table 2), 
a significant difference in the sdLDL-C concentration was only 
found between subgroups divided according to TG criteria. There 
were no differences in sdLDL-C concentration in the presence 
or absence of other MetS components. A similar pattern was 
observed for healthy controls. Subjects who met the TG criteria 
showed a higher sdLDL-C concentration than those who did 
not. In addition, sdLDL-C concentration was significantly differ-
ent between healthy controls who met the WC criteria and those 
who did not. 
 The ratio of sdLDL-C/LDL-C was also significantly increased in 
subjects who met the TG criteria, regardless of gender or dis-
ease status (Table 2). However, the presence or absence of the 
WC component did not significantly alter this ratio. A difference 
in the sdLDL-C/LDL-C ratio was observed between healthy men 
who met the HDL-C criteria and those who did not. 
3.  Association of the sdLDL-C concentration with other 
metabolic parameters
Among those univariate correlations analysis in all subjects; TC, 
LDL-C, and TG each showed moderate correlation with sdLDL-C 
concentration (r=0.738, 0.508, and 0.543, respectively, for men; 
0.748, 0.692, and 0.653, respectively, for women), whereas only 
TG showed moderate correlation with sdLDL-C/LDL-C ratio (r= 
0.789 for men; 0.745 for women). 
 When subpopulations divided according to MetS status were 
analyzed, in the healthy group, TC, LDL-C, and TG each showed 
moderate correlation with sdLDL-C concentration (r=0.665, 0.574, 
and 0.659 for TC, LDL-C, and TG, respectively), whereas only 
TG showed moderate correlation with sdLDL-C/LDL-C ratio (r= 
0.749). In the MetS group, the strength of the correlation be-
tween TG and sdLDL-C concentration was diminished (r=0.403), 
while other factors retained moderate correlation with sdLDL-C 
(r=0.589 for TC; 0.752 for LDL-C). However, only TG showed 
moderate correlation with sdLDL-C/LDL-C ratio (r=0.767). 
 To elucidate each factor’s quantitative contribution to the sdLDL-
Fig. 1. Scattergrams of the small dense LDL cholesterol (sdLDL-C) concentrations in a healthy population versus male (A) and female (B) 
patients with metabolic syndrome. The lines depict the median values and and interquartile ranges of each group, which were significantly 
different (P <0.001) in both genders.
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C concentration and the sdLDL-C/LDL-C ratio, multiple linear 
regression analysis using anthropometric and metabolic param-
eters was conducted for the whole study population (Table 3). 
The most significant determinant of plasma sdLDL-C concentra-
tion was LDL-C, followed by TG concentration, and fasting glu-
cose level; WC in men and age in women apparently had an ad-
ditive effect on sdLDL-C concentration. For the sdLDL-C/LDL-C 
ratio, TG concentration was the most significant contributing fac-
tor in both genders.
 LDL-C, TG, fasting glucose and WC were common significant 
determinants of plasma sdLDL-C in both MetS and healthy sub-
jects (Table 4). However, the effect of LDL-C was no longer ob-
served when sdLDL-C/LDL-C ratio was used as the dependent 
factor. The regression coefficients of TG for sdLDL-C concentra-
tion and sdLDL-C/LDL-C ratio in the healthy group (0.2706 and 
9.1815, respectively) were noticeably higher than in the MetS 
group (0.1747 and 6.9518, respectively), consistent with the di-
minished strength of correlation between TG and sdLDL-C con-
centration in the MetS group. While the association between DBP 
and sdLDL-C concentration or sdLDL-C/LDL-C ratio was only 
significant in the MetS group, HDL-C concentration showed sig-
nificant association with sdLDL-C concentration and sdLDL-C/
LDL-C ratio in the healthy population only (Table 4).
Table 3. Associations of the sdLDL-C concentration and sdLDL-C/LDL-C ratio with metabolic variables in each gender determined by multi-
ple linear regression analysis
Parameter
Men (n=406) Women (n=401)
sdLDL-C (mmol/L) sdLDL-C/LDL-C (%) sdLDL-C (mmol/L) sdLDL-C/LDL-C (%)
β±SE P value β±SE P value β±SE P value β±SE P value
Age (yr) 0.0006±0.0016 0.7126 0.0363±0.0456 0.4259 0.0042±0.0012 0.0007* 0.1638±0.0379 <0.0001*
WC (cm) 0.0078±0.0022 0.0005* 0.2501±0.0644 0.0001* 0.0004±0.0018 0.8129 0.0269±0.0535 0.6150 
SBP (mm Hg) -0.0029±0.0017 0.0873 -0.1066±0.0490 0.0303* -0.0001±0.0012 0.9223 -0.0007±0.0363 0.9836 
DBP (mm Hg) 0.0036±0.0020 0.0713 0.0969±0.0588 0.1000 0.0013±0.0016 0.4366 0.0502±0.0497 0.3131 
Fasting glucose (mmol/L) 0.0198±0.0099 0.0467* 0.4983±0.2903 0.0868 0.0215±0.0068 0.0017* 0.4732±0.2069 0.0227*
TG (mmol/L) 0.1776±0.0112 <0.0001* 7.4390±0.3270 <0.0001* 0.2420±0.0143 <0.0001* 7.3739±0.4339 <0.0001*
HDL-C (mmol/L) 0.0430±0.0617 0.4864 3.3684±1.8020 0.0623 0.0441±0.0404 0.2767 -0.0022±1.2312 0.9986 
LDL-C (mmol/L) 0.3911±0.0204 <0.0001* 0.3981±0.5957 0.5043 0.3005±0.0137 <0.0001* -0.1538±0.4164 0.7122 
The components of metabolic syndrome (WC, TG, HDL-C, SBP, DBP, fasting glucose), age, and LDL-C were included in the multiple linear regression analy-
sis with an “enter” procedure, and P values <0.05 are indicated by *.
Abbreviations: See Table 1. 
Table 4. Associations of the sdLDL-C concentration and sdLDL-C/LDL-C ratio with metabolic variables in patients with metabolic syndrome 
and healthy controls
Parameter
MetS (n=447) Healthy population (n=360)
sdLDL-C (mmol/L) sdLDL-C/LDL-C (%) sdLDL-C (mmol/L) sdLDL-C/LDL-C (%)
β±SE P value β±SE P value β±SE P value β±SE P value
Age (yr) 0.0025±0.0016 0.1183 0.0698±0.0455 0.1257 0.0022±0.0013 0.0764 0.0780±0.0406 0.0557 
WC (cm) 0.0045±0.0019 0.0226* 0.1200±0.0561 0.0329* 0.0055±0.0018 0.0020* 0.2161±0.0571 0.0002*
SBP (mm Hg) -0.0024±0.0013 0.0729 -0.0653±0.0388 0.0927 0.0003±0.0016 0.8678 -0.0255±0.0521 0.6241 
DBP (mm Hg) 0.0047±0.0018 0.0102* 0.1303±0.0521 0.0127* -0.0006±0.0018 0.7561 0.0102±0.0585 0.8612 
Fasting glucose (mmol/L) 0.0172±0.0068 0.0121* 0.4015±0.1966 0.0418* 0.0990±0.0277 0.0004* 3.0126±0.8919 0.0008*
TG (mmol/L) 0.1747±0.0105 <0.0001* 6.9518±0.3011 <0.0001* 0.2706±0.0157 <0.0001* 9.1815±0.5049 <0.0001*
HDL-C (mmol/L) 0.0077±0.0634 0.9030 0.4235±1.8250 0.8166 0.0935±0.0425 0.0287* 3.0332±1.3720 0.0277*
LDL-C (mmol/L) 0.3830±0.0167 <0.0001* -0.0060±0.4802 0.9900 0.2510±0.0160 <0.0001* -0.6816±0.5151 0.1866 
The components of metabolic syndrome (WC, TG, HDL-C, SBP, DBP, fasting glucose), age, and LDL-C were included in the multiple linear regression analy-
sis with an “enter” procedure, and P values <0.05 are indicated by *.
Abbreviations: See Table 1.
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DISCUSSION
In this study, we evaluated sdLDL-C concentration in both healthy 
subjects and patients with MetS. The study population was sub-
divided according to the presence or absence of each MetS com-
ponent, and the concentration of sdLDL-C and the sdLDL-C/LDL-
C ratio in each subgroup were compared. We found that the 
sdLDL-C concentration and sdLDL-C/LDL-C ratio were higher in 
patients with MetS who met TG component criteria compared 
with those who did not (Table 2), while the other MetS compo-
nents were not associated with an elevated sdLDL-C concentra-
tion. The findings were reproducible in both genders and also in 
the healthy population, with an exception that additional effect 
of WC or HDL-C on the concentration of sdLDL-C or sdLDL-C/
LDL-C ratio was found in healthy group. A possible explanation 
of this phenomenon is a larger effect of TG on sdLDL-C com-
pared with that of WC or HDL-C, which would be sufficient to 
make a statistically significant difference even in patients with 
MetS whose baseline for sdLDL-C is higher than that of healthy 
population.
 In correlation and multiple linear regression analyses, the TG 
concentration was a significant determinant of sdLDL-C concen-
tration (Tables 3 and 4), in line with the previous studies on the 
association between sdLDL-C and TG concentrations [17, 18, 
22]. However, to the best of our knowledge, none of these stud-
ies analyzed differences in sdLDL-C concentration according to 
the presence or absence of each MetS component as done in 
this study. A previous cross-sectional study on the relationship 
between sdLDL particle number, measured by nuclear magnetic 
resonance, and each MetS component also showed that only 
TG and HDL-C concentrations were strongly correlated with sdLDL 
particle number [15].
 The precise mechanism underlying the association between 
TG and sdLDL-C concentrations has not yet been elucidated. It 
has been speculated that, when the TG concentration is normal, 
cholesteryl ester transfer protein preferentially mediates the trans-
fer of HDL cholesteryl esters to LDL particles [23, 24]. In hyper-
triglyceridemia, the large very low-density lipoprotein (VLDL) par-
ticles are preferred acceptors of HDL-derived cholesteryl esters 
owing to their increased numbers [23, 24]. Under these condi-
tions, there are high net transfer rates of cholesteryl esters from 
HDL to VLDL, and of TG from VLDL to both LDL and HDL. The 
TG-enriched LDL particles are targets for hepatic lipase activity 
that hydrolyzes phospholipid and TG, leading to the formation of 
sdLDL particles [23, 24]. 
 TG concentration is an independent risk factor in the devel-
opment of CVD [25-27]. While the number of TG-rich lipopro-
tein particles or level of TG-rich lipoprotein cholesterol could con-
tribute to the development of atherosclerosis in hypertriglyceri-
demia, alterations in other lipoprotein phenotypes induced by 
hypertriglyceridemia could also be important factors in this pro-
cess [28]. An increased number of remnant-like lipoproteins 
and sdLDL particles were simultaneously present in fasting hy-
pertriglyceridemia or postprandial lipidemia, and in both cases, 
highly atherogenic [28]. In the present study, the TG concentra-
tion showed relatively strong correlation with sdLDL-C concen-
tration, and is considered a significant determinant of sdLDL-C 
concentration (Table 3). And the association between sLDL-C/
LDL-C ratio, which may rise due to increased sdLDL without an 
increase of LDL, and TG was even stronger than that between 
sdLDL-C concentration and TG (Table 4), as reported previously 
[18]. These findings suggest that the atherogenic effect of hy-
pertriglyceridemia partially results from an increased sdLDL. How-
ever, more studies are needed to elucidate the primary mecha-
nism that leads to the atherogenic effect mediated by TG.
 To our surprise, the correlation of TG with sdLDL-C previously 
was weakened in the MetS group compared with the healthy 
group, and the contribution of TG to the sdLDL-C previously was 
consistently diminished in the MetS group (Table 4). When each 
group was subdivided according to whether they had hypertri-
glyceridemia (TG>1.7 mmol/L) or not, the regression coefficient 
of TG for sdLDL-C previously was weakened by the presence of 
hypertriglyceridemia in both the MetS and healthy groups (Sup-
plemental Data Table S1). This implies that a more complicated 
mechanism of lipid metabolism contributed to the sdLDL-C con-
centration in MetS or hypertriglyceridemia compared with the 
healthy group, particularly having a normal TG concentration. 
 WC is regarded as a key component of MetS, as central obe-
sity could drive all the pathophysiologic conditions constituting 
the other criteria of this syndrome [29]. Obesity itself also results 
in an increase in the formation of sdLDL by inducing changes in 
lipoprotein metabolism [30, 31]. In the present study, healthy 
individuals who had an abnormal WC showed an increased sdLDL-
C concentration; this tendency was not observed in patients with 
MetS (Table 2). Multiple linear regression analysis revealed this 
relationship as concordantly significant in both groups (Table 4), 
but relatively small contributions of WC to sdLDL-C concentra-
tion were noted (regression coefficients: 0.0055±0.0018 and 
0.0045±0.0019, in the healthy and MetS group, respectively). 
While obesity is the major driving force of the other components 
of MetS, insulin resistance and compensatory hyperinsulinemia 
could predispose individuals to conditions related to CVD [32], 
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and the insulin resistance correlates well with sdLDL-C concen-
tration [33]. In the present study using HOMA-IR as an indica-
tor of insulin resistance, weak correlation between insulin resis-
tance and both sdLDL-C concentration and sdLDL-C/LDL-C ra-
tio was observed (r=0.366 and 0.315, respectively). And the 
strength of correlation was weakened in the MetS group com-
pared with the healthy population (Supplemental Data Figure 
S1). 
 Low HDL-C concentration, in conjunction with hypertriglyceri-
demia and presence of sdLDL, constitutes the so-called athero-
genic lipoprotein phenotype [34]. However, in the present study, 
while HDL-C concentration significantly contributed to LDL-C 
concentration and sdLDL-C/LDL-C ratio in the healthy popula-
tion, it did not do so in patients with MetS (Table 4), opposite to 
the reported correlation between sdLDL particle number and 
HDL-C concentration in MetS [15]. As there seem to be differ-
ent contributions of HDL subfractions to sdLDL-C, HDL2-C be-
ing more closely correlated with sdLDL-C than total HDL-C or 
HDL3-C [35], further studies utilizing HDL-C subfractions are 
needed to elucidate their association with sdLDL-C level or sdLDL-
C/LDL-C ratio in patients with MetS.
 In the Framingham Heart Study, hypertension and sdLDL par-
ticle number were significantly correlated in the MetS group [15]. 
In line with this report, both the sdLDL-C concentration and sd-
LDL-C/LDL-C ratio were significantly associated with DBP in the 
MetS group (Table 4). However, these associations were not ob-
served in the healthy population. A study comparing LDL sub-
fraction patterns of normotensive and hypertensive individuals 
without MetS also concluded that hypertension per se did not 
increase the proportion of sdLDL particles in this population [36]. 
Taken together, hypertension is the only factor among compo-
nents of MetS that is more closely associated to sdLDL-C con-
centration in MetS than in healthy population. Thus there might 
be a different contribution of hypertension to the formation of 
sdLDL in MetS.
 When the total number of MetS components was regarded as 
a simple tentative surrogate marker for the severity of MetS, it 
was found to be well associated with the number of sdLDL par-
ticles [15]. In our study, the sdLDL-C concentration and sdLDL-
C/LDL-C ratio were concordantly elevated with the increasing 
number of MetS components, although the sdLDL-C concentra-
tion was not significantly different between MetS patients who 
had four and five MetS components (Supplemental Data Figure 
S2). 
 This study has several limitations. As the study population 
was selected from a cohort to give nearly equal numbers in the 
subgroups, the natural distribution of metabolic parameters in 
the general population was abolished. Furthermore, because of 
differences in measurement methods and the ethnicity of the 
study population, our results are not directly comparable with 
those of previous studies [37].
 In conclusion, among five MetS components, abnormal TG 
concentration was the only factor associated with sdLDL-C con-
centration and sdLDL-C/LDL-C ratio in both genders with or with-
out MetS. In addition, TG concentration showed the strongest 
correlation with sdLDL-C concentration and sdLDL-C/LDL-C ra-
tio among the five MetS components. Therefore, hypertriglyceri-
demia is a major factor associated with elevated concentrations 
of sdLDL-C in patients with MetS. Our results support the hy-
pothesis that the atherogenic effect of hypertriglyceridemia is 
mediated by increased sdLDL-C; further studies are required to 
elucidate the underlying mechanism.
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